CMS Grants Transitional Pass-Through Payment Status to Lantheus (LNTH) PYLARIFY TruVu Injection

gurufocus.com · 2026-09-30

On September 30, 2026, Lantheus Holdings Inc (NASDAQ: LNTH) announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Thro

TickrTrends take: Lantheus received transitional pass-through payment status from CMS for PYLARIFY TruVu Injection, which provides temporary enhanced reimbursement for eligible new medical technologies. Given TickrTrends' current overvalued assessment, investors should monitor whether this reimbursement advantage translates into revenue growth sufficient to justify the current valuation, as the pass-through status is temporary and will eventually revert to standard Medicare payment rates. The Healthcare sector's competitive dynamics mean that reimbursement wins alone may not alter the valuation picture without corresponding improvements in market adoption and long-term revenue sustainability.

Read the full story at gurufocus.com →